Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.24.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash Flows From Operating Activities    
Net income (loss) $ 3,810 $ (88)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Depreciation and amortization 205 954
Interest accretion expense 34 92
Amortization of deferred financing fees 42
Stock-based compensation 218 501
Bad debt expense reversal (100)
Credit loss expense 26
Change in fair value of note payable 445 400
Amortization on operating lease right of use asset 332 461
Other changes in operating assets and liabilities:    
Accounts receivable (2,336) 202
Other current assets 237 176
Accounts payable 137 228
Accrued salaries and bonus (320) (157)
Other accrued expenses 870 (118)
Operating lease liabilities (355) (292)
Other long-term liabilities 259 248
Net cash provided by operating activities 3,462 2,649
Cash Flows From Investing Activity    
Working capital adjustment on sale of Interpace Pharma Solutions (117)
Proceeds from sale of Interpce Pharma Solutions, net 500
Purchase of property and equipment (747) (328)
Net cash (used in) provided by investing activities (747) 55
Cash Flows From Financing Activities    
Payments made on note payable (4,100)
Payments on line of credit (2,500)
Net cash used in financing activities (4,100) (2,500)
Net (decrease) increase in cash and cash equivalents (1,385) 204
Cash and cash equivalents from continuing operations– beginning 3,498 4,828
Cash and cash equivalents from discontinued operations– beginning
Cash and cash equivalents – beginning 3,498 4,828
Cash and cash equivalents from continuing operations– ending 2,113 5,032
Cash and cash equivalents from discontinued operations– ending
Cash and cash equivalents – ending $ 2,113 $ 5,032